



# SYNTHESIS OF NEW CONDENSATION PRODUCT OF HYDROXY COUMARIN

O.S. Chavan<sup>1</sup>, S.B. Chavan<sup>2</sup>, M.A. Sakhare<sup>3</sup>, M.A. Baseer<sup>2</sup>\*

<sup>1</sup>Badrinarayan Barwale College, Jalna-431203,MS,India.,<sup>2</sup>Yashwant College, Nanded, MS,India.,<sup>3</sup>Balbheem College, Beed,MS,India.

#### Abstract

A Series of new coumarin derivatives (1-8) was synthesized by condensation of 4-hydroxy coumarin with appropriate chloro compounds by using simple, efficient and generally applicable method. The structures of all compounds were confirmed by elemental analysis and spectral data.

**Introduction**: 4-hydroxy coumarin and their derivatives have been reported to exhibit a broad spectrum of biological activities, such as analgesic<sup>1</sup>, anti- arthritis<sup>2</sup>, anti-inflammatory<sup>3</sup>, anti-pyretic<sup>4</sup>, anti-bacterial<sup>5</sup>,anti-viral<sup>6</sup>,anti- cancer<sup>7</sup>, and anti-microbial activity<sup>8</sup>. A number of comparatives pharmacological investigations of 4-hydroxy coumarin derivatives have shown good anti-coagulant activity combined with low side effect and little toxicity<sup>9</sup>. In synthesis, structure modification and very wide variety of biological activities of 4-hydroxy coumarin have been reported in many research papers<sup>10,11,12,13,14</sup>. On the basis of above all properties of 4-hydroxy coumarin and its derivatives, we decide to synthesizenew derivatives of 4-hydroxy coumarin by well known method<sup>15</sup>.

Fig. I









Table I : Characterization data of compounds prepared.

Compounds	Mol. For	<b>MP(0C)</b>	Yield(%)
1	$C_{11}H_8O_5$	240	82
2	$C_{16}H_{10}O_{6}$	352	75
3	C <sub>15</sub> H <sub>9</sub> NO <sub>5</sub>	-	70
4	$C_{15}H_{10}O_4$	265	81
5	C <sub>16</sub> H <sub>9</sub> ClO <sub>4</sub>	260	80
6	$C_{15}H_{10}O_3$	152	90
7	C <sub>16</sub> H <sub>10</sub> O <sub>5</sub>	332	85
8	$C_{16}H_{10}O_5$	335	77



Where, A = Cl-ACOH, B= Para-Cl-Salicylic Acid, C= Para Cl-Nitro Benzene, D= Para C l-Phenol E= 2,4-Di-Cl-benzaldehyde, F= Cl-Benzene, G= 4-Cl-Salicyladehyde, H= 4-Cl-B enzoic Acid



Journal of Medicinal Chemistry and Drug Discovery ISSN: 2347-9027 Special Issue Analytical Chemistry Teachers And Researchers Association National Convention/Seminar 18 January 2015



# Experimental

Meltngpoints weredetermined in open capillary tubes and are uncorrected. The FT-IR spectra were recorded in KBrpallets on a shimandzu FT-IR spectrophotometer.<sup>1</sup>H-NMR spectra were recorded on a 200 MHz by using TMS as a internal Std. Chemical shift expressed in  $\delta$ ppm.All compounds gave satisfactory C,H,N analysis.The physical characterization data are presented in table-I.

Synthesisof 1-8

A mixture of compounds 4-hydroxy coumarin (0.01 mol), and corresponding chloro compounds (0.02 mol), and 10 % NaOH (20ml) in ethanol (30 ml) was refluxed on a water bath for 3 Hrs. The reaction mixture was cooled and poured onto crushed ice. The solid obtained was filtered, dried and recrystalliedfrom a suitable solvent to afford the desired product.

1: IR (KBr cm<sup>-1</sup>): 1110 (C-O-C Str), 1738 (C=O Acidic gr Str), 2937 (C-H Ali Str) , 3062 (C-H ArStr).

NMR (CDCl<sub>3</sub> $\delta$  ppm): 6.9-7.30(m,4H,Ar-H), 5.07(s,1H,ethylene),4.89 (s,2H,methylene), 11.05(s,1H,O-H)

MS m/z: 220 (bp),221(M+1).

Elemental Analysis: C, 60.01; H, 3.68; O, 36.08.

2:IR (KBr cm<sup>-1</sup>): 1100 (C-O-C Str), 1737 (C=O Acidic gr Str), 3055 (C-H ArStr), 3360 (O-H broad Str).

NMR (CDCl<sub>3</sub>δ ppm):6.5-7.80(m,7H,Ar-H), 5.62(s,1H,ethylene), 5.02(s,1H,O-H), 10.9(s,1H,COO-H)

MS m/z:298.0 (bp), 299 (M+1), 300 (M+2).

Elemental Analysis:C,64.50; H,3.4; O,32.02.

3:IR (KBr cm<sup>-1</sup>): 1310 (C-O-C Str), 1610 (Ar-NO<sub>2</sub>str), 1735 (lactone C=O Str), 3066 (C-H ArStr).

NMR (CDCl<sub>3</sub>δ ppm): 7.02-7.99(m,8H,Ar-H), 5.62(s,1H,ethylene),

MS m/z: 283 (bp), 284(M+1), 285.





Elemental Analysis:C,63.6; H,3.30; O,28.30.

4:IR (KBr cm<sup>-1</sup>): 860,844,829 (sub. Benzene Str), 1710 (C=O Str), 3066 (C-H ArStr), 3366 (O-H broad Str).

NMR (CDCl<sub>3</sub>δ ppm): 6.5-7.30(m,8H,Ar-H), 5.61(s,1H,ethylene), 5.01(s,1H,O-H),

MS m/z: 254 (bp), 255(M+1), 256.

Elemental Analysis: C, 71.01; H, 4.01; O,25.0.

5:IR (KBr cm<sup>-1</sup>):559 (Ar-C-ClStr), 1734 (lactone C=O Str), 1705 (C=O Str), 1050 (C-O-C Str).

NMR (CDCl<sub>3</sub>δ ppm): 6.8-7.60(m,7H,Ar-H), 5.60 (s,1H,ethylene), 10.20(s,1H,CHO).

MS m/z: 300(bp), 301 ,302.

Elemental Analysis: C,64.0; H,3.0; O,21.3.

6:IR (KBr cm<sup>-1</sup>): 1210 (C-O-C Str), 1730 (lactone C=O Str), 3056 (C-H ArStr).

NMR (CDCl<sub>3</sub>δ ppm):6.5-7.29 (m,9H,Ar-H), 5.5 (s,1H,ethylene).

MS m/z:238 (bp),239, 240.

Elemental Analysis: C, 76.02; H,4.20; O,20.10.

7:IR (KBr cm<sup>-1</sup>): 3059 (C-H ArStr), 1090 (C-O-C Str), 3350 (O-H Str broad), 1710 (C=O Str).

NMR (CDCl<sub>3</sub>δ ppm): 6.4-7.30(m,7H,Ar-H), 6.3 (s,1H,ethylene), 5.01(s,1H,O-H), 10.30(s,1H,CHO).

MS m/z: 282 (bp), 283,284.

Elemental Analysis: C,68.0; H,3.6; O,28.02.

8:IR (KBr cm<sup>-1</sup>): 1152 (C-O-C Str), 1708 (lactone C=O Str), 1738 (C=O Acidic gr Str).

NMR (CDCl<sub>3</sub>δ ppm): 6.9-7.9 (m,8H,Ar-H), 5.65 (s,1H,ethylene), 10.98 (s,1H,COO-H).

MS m/z: 282(bp),283,284.

Elemental Analysis: C,67.8; H,3.60; O,28.09.





### Acknowledgment

Authors are thankful to UGC for financial support and Principal, Yashwant College Nanded, for providing necessary laboratory facility with constant encouragement throughout the research work.

## References

- 1. E. Adimi, E.Marazzi-Uberti, C.Turba, Analgecis action of 4-hydroxy coumarin-Arch.Ital.Sci.Farmacol., 9(1959),61.
- 2. D. Chiarino, G. C. Grancini, V. Frigeni, A. Carenzi, Eur. Pat. Appl., EP284017, (1988).
- 3. A. C. Luchini, P. Rodrigues-Orsi, S. H.Cestari, L. N. Seito, A.Witaicenis, C. H. Pellizzon, L. C. D. Stasi, *Biol. Pharm. Bull.*, *31* (2008),1343.
- 4. P. Stern, M.Dezelic, R. Kosak, *NaunynSchmiedebergs Arch.Exp.Pathol.Pharmakol.*, 232(1957), 356.
- 5. Z. H. Cholan, A. U. Shaikh, A.Rauf, C. T. Supuran, J. Enz. Inhib. Med. Chem., 21 (2006), 741.
- 6. B. S. Kirkiacharian, E. Clevcq, R.Kurkjian, C. Pannecouqe, *J.Pharma. Chem.*, 42 (2008), 265.
- 7. M. A. Velasco-Velazquez, J.Agramoute-Heva, D.Barrra, A. Jimenez-Orozco, M. J.Garcia-Mondragon, N. M.Patino, A. Landa, J.Mandoki, *CancerLett.*, 198 (2003), 179.
- 8. Milan Mladenovic, N. NenadVukovicneda, S. Slobodan, and S. Slavica, *Molecules.*, 14 (2009), 1495.
- 9. I. Manolov, C. Maichle-Mossemer, N.Danchev, Eur. J. Med. Chem., 41(2006), 882.
- 10. N. Au, A. E. Rettie, DrugMetab. Rev., 40 (2008), 355.
- 11. N. Humdi, M. Saoud, A.Romerosa, R. B.Hasan, J. Heterocyclic Chem., 45 (2008), 1835.
- 12. J. C. Jung, J. H.Lee, S. Oh, J.G. Lee, O. S. Park, *Bioorg.Med.Chem. Lett.*, 14 (2004), 5527.
- 13. K.N.Venugopala, B. S. Jayashree, Indian J.Heterocyclic Chem., 12 (2003), 307.
- 14. Gopal Krishna Rao, K.N.Venugopala, and P. N. Sanjay Pai, *Indian J.Heterocyclic Chem.*, 17 (2008),397.
- 15. V.H.Masand, K.N.Patil, V.T.Humne, Nasirbaig, *Indian J.Heterocyclic Chem.*, 17 (2008), 375.